此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis (SAVE-AS)

2026年11月13日 更新者:Sung-Ji Park、Samsung Medical Center

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)

Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.

SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.

研究概览

详细说明

Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).

Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.

Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.

Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.

Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).

Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.

Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).

研究类型

介入性

注册 (估计的)

1182

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Busan、韩国
        • 尚未招聘
        • Dong-A University Hospital
        • 首席研究员:
          • Kyung Hee Lim, MD, PhD
      • Changwon、韩国
        • 尚未招聘
        • Samsung Changwon Hospital
        • 首席研究员:
          • Mirae Lee, MD, PhD
      • Cheonan、韩国
        • 尚未招聘
        • Dankook University Hospital
        • 首席研究员:
          • Su Yeon Lee, MD, PhD
      • Gwangmyeong、韩国
        • 尚未招聘
        • Chung-Ang University Gwangmyeong Hospital
        • 首席研究员:
          • Eun Jeong Cho, MD, PhD
      • Seongnam、韩国
        • 尚未招聘
        • Seoul National University Bundang Hospital
        • 首席研究员:
          • Jiesuck Park, MD, PhD
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center
        • 接触:
        • 首席研究员:
          • Sung-Ji Park, MD, PhD
      • Seoul、韩国
        • 尚未招聘
        • Korea University Anam Hospital
        • 首席研究员:
          • So Ree Kim, MD, PhD
      • Seoul、韩国
        • 尚未招聘
        • Kangbuk Samsung Hospital
        • 首席研究员:
          • Jiwon Kim, MD, PhD
      • Seoul、韩国
        • 尚未招聘
        • Konkuk University Medical Center
        • 首席研究员:
          • Sung Hea Kim, MD, PhD
      • Seoul、韩国
        • 尚未招聘
        • Asan Medical Center, University of Ulsan College of Medicine
        • 首席研究员:
          • Dae-Hee Kim, MD, PhD
      • Seoul、韩国
        • 尚未招聘
        • Severance Hospital, Yonsei University College of Medicine
        • 首席研究员:
          • Chi Young Shim, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Able to understand the study protocol and provide written informed consent
  • Adults aged 19 years or older
  • Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
  • Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
  • Left ventricular ejection fraction 50% or higher
  • Asymptomatic, New York Heart Association (NYHA) functional class I

Exclusion Criteria:

  • Left ventricular ejection fraction below 50%
  • Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
  • Symptomatic severe aortic stenosis
  • Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
  • Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
  • NYHA functional class II to IV
  • Use of an SGLT2 inhibitor within the previous 3 months
  • Known hypersensitivity to SGLT2 inhibitors
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
  • Type 1 diabetes mellitus
  • Pregnancy or breastfeeding
  • Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
  • Life expectancy below 2 years, or inability to comply with the study protocol
  • Diabetic ketoacidosis
  • Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
  • Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
  • Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Enavogliflozin

Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy.

Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.

其他名称:
  • 环境
安慰剂比较:Placebo

Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy.

Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure
大体时间:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

次要结果测量

结果测量
措施说明
大体时间
All-cause death
大体时间:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to death from any cause after randomization.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Aortic valve replacement
大体时间:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first surgical or transcatheter aortic valve replacement after randomization.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Hospitalization for heart failure
大体时间:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics).

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Cardiac death
大体时间:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Change from baseline in aortic valve peak velocity
大体时间:Baseline, 12 months, and 24 months

Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in mean transaortic pressure gradient
大体时间:Baseline, 12 months, and 24 months

Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in aortic valve area
大体时间:Baseline, 12 months, and 24 months

Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in dimensionless index (velocity ratio)
大体时间:Baseline, 12 months, and 24 months

Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless.

Baseline, 12 months, and 24 months
Change from baseline in left ventricular mass
大体时间:Baseline, 12 months, and 24 months

Change in echocardiographic left ventricular mass (g).

Baseline, 12 months, and 24 months
Change from baseline in left ventricular global longitudinal strain
大体时间:Baseline, 12 months, and 24 months

Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in left ventricular ejection fraction
大体时间:Baseline, 12 months, and 24 months

Change in left ventricular ejection fraction (%) by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in NT-proBNP
大体时间:Baseline, 12 months, and 24 months

Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL).

Baseline, 12 months, and 24 months
Annual eGFR slope
大体时间:From baseline through 24 months

Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year.

From baseline through 24 months
Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)
大体时间:From first dose of study drug through 7 days after the last dose (up to approximately 25 months)

Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL [3.9 mmol/L] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria.

From first dose of study drug through 7 days after the last dose (up to approximately 25 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sung-Ji Park, MD, PhD、Samsung Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月10日

初级完成 (估计的)

2031年6月1日

研究完成 (估计的)

2031年6月1日

研究注册日期

首次提交

2026年11月5日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2025-07-028
  • KCT0012093 (注册表标识符:Clinical Research Information Service (CRIS), Republic of Korea)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅